Report Detail
Global (United States, European Union and China) Prostate Cancer Drugs Market Research Report 2019-2025
- RnM3446644 |
- 29 May, 2020 |
- Global |
- 102 Pages |
- QYResearch |
- Pharma & Healthcare
This report covers market size and forecasts of Prostate Cancer Drugs, including the following market information:
Global Prostate Cancer Drugs Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Prostate Cancer Drugs Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Prostate Cancer Drugs Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Prostate Cancer Drugs Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K MT)
Key market players
Major competitors identified in this market include AbbVie, Astellas Pharma, Astra Zeneca, Johnson & Johnson, Sanofi, GlaxoSmithKline, Merck Group, Novartis, Amgen, Bayer HealthCare, Ferring Pharmaceutical, Janssen Pharmaceuticals, Endo Pharmaceuticals, BMS, Takeda Pharmaceuticals, Northwest Biotherapeutics, Teva Pharmaceutical, Boehringer Ingelheim, Foresee Pharmaceuticals, Tokai Pharmaceuticals, Spectrum Pharmaceuticals, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Hormonal Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Based on the Application:
Clinics
Hospitals
Other
- 1.4.1 Research Process
- 1.4.2 Data Triangulation
- 1.4.3 Research Approach
- 1.4.4 Base Year
- 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
- 1.5.2 Covid-19 Impact: Commodity Prices Indices
- 1.5.3 Covid-19 Impact: Global Major Government Policy
2 Global Prostate Cancer Drugs Quarterly Market Size Analysis
- 2.1 Prostate Cancer Drugs Business Impact Assessment - COVID-19
- 2.1.1 Global Prostate Cancer Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.1.2 Global Prostate Cancer Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.2 Global Prostate Cancer Drugs Quarterly Market Size 2020-2021
- 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
- 2.3.1 Drivers
- 2.3.2 Restraints
- 2.3.3 Opportunities
- 2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
- 3.1 Global Prostate Cancer Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
- 3.2 Global Prostate Cancer Drugs Factory Price by Manufacturers
- 3.3 Location of Key Manufacturers Prostate Cancer Drugs Manufacturing Factories and Area Served
- 3.4 Date of Key Manufacturers Enter into Prostate Cancer Drugs Market
- 3.5 Key Manufacturers Prostate Cancer Drugs Product Offered
- 3.6 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Prostate Cancer Drugs Segments, By Type
- 4.1 Introduction
- 1.4.1 Hormonal Therapy
- 1.4.2 Chemotherapy
- 1.4.3 Immunotherapy
- 1.4.4 Targeted Therapy
- 4.2 By Type, Global Prostate Cancer Drugs Market Size, 2019-2021
- 4.2.1 By Type, Global Prostate Cancer Drugs Market Size by Type, 2020-2021
- 4.2.2 By Type, Global Prostate Cancer Drugs Price, 2020-2021
5 Impact of Covid-19 on Prostate Cancer Drugs Segments, By Application
- 5.1 Overview
- 5.5.1 Clinics
- 5.5.2 Hospitals
- 5.5.3 Other
- 5.2 By Application, Global Prostate Cancer Drugs Market Size, 2019-2021
- 5.2.1 By Application, Global Prostate Cancer Drugs Market Size by Application, 2019-2021
- 5.2.2 By Application, Global Prostate Cancer Drugs Price, 2020-2021
6 Geographic Analysis
- 6.1 Introduction
- 6.2 North America
- 6.2.1 Macroeconomic Indicators of US
- 6.2.2 US
- 6.2.3 Canada
- 6.3 Europe
- 6.3.1 Macroeconomic Indicators of Europe
- 6.3.2 Germany
- 6.3.3 France
- 6.3.4 UK
- 6.3.5 Italy
- 6.4 Asia-Pacific
- 6.4.1 Macroeconomic Indicators of Asia-Pacific
- 6.4.2 China
- 6.4.3 Japan
- 6.4.4 South Korea
- 6.4.5 India
- 6.4.6 ASEAN
- 6.5 Rest of World
- 6.5.1 Latin America
- 6.5.2 Middle East and Africa
7 Company Profiles
- 7.1 AbbVie
- 7.1.1 AbbVie Business Overview
- 7.1.2 AbbVie Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.1.3 AbbVie Prostate Cancer Drugs Product Introduction
- 7.1.4 AbbVie Response to COVID-19 and Related Developments
- 7.2 Astellas Pharma
- 7.2.1 Astellas Pharma Business Overview
- 7.2.2 Astellas Pharma Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.2.3 Astellas Pharma Prostate Cancer Drugs Product Introduction
- 7.2.4 Astellas Pharma Response to COVID-19 and Related Developments
- 7.3 Astra Zeneca
- 7.3.1 Astra Zeneca Business Overview
- 7.3.2 Astra Zeneca Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.3.3 Astra Zeneca Prostate Cancer Drugs Product Introduction
- 7.3.4 Astra Zeneca Response to COVID-19 and Related Developments
- 7.4 Johnson & Johnson
- 7.4.1 Johnson & Johnson Business Overview
- 7.4.2 Johnson & Johnson Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.4.3 Johnson & Johnson Prostate Cancer Drugs Product Introduction
- 7.4.4 Johnson & Johnson Response to COVID-19 and Related Developments
- 7.5 Sanofi
- 7.5.1 Sanofi Business Overview
- 7.5.2 Sanofi Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.5.3 Sanofi Prostate Cancer Drugs Product Introduction
- 7.5.4 Sanofi Response to COVID-19 and Related Developments
- 7.6 GlaxoSmithKline
- 7.6.1 GlaxoSmithKline Business Overview
- 7.6.2 GlaxoSmithKline Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.6.3 GlaxoSmithKline Prostate Cancer Drugs Product Introduction
- 7.6.4 GlaxoSmithKline Response to COVID-19 and Related Developments
- 7.7 Merck Group
- 7.7.1 Merck Group Business Overview
- 7.7.2 Merck Group Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.7.3 Merck Group Prostate Cancer Drugs Product Introduction
- 7.7.4 Merck Group Response to COVID-19 and Related Developments
- 7.8 Novartis
- 7.8.1 Novartis Business Overview
- 7.8.2 Novartis Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.8.3 Novartis Prostate Cancer Drugs Product Introduction
- 7.8.4 Novartis Response to COVID-19 and Related Developments
- 7.9 Amgen
- 7.9.1 Amgen Business Overview
- 7.9.2 Amgen Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.9.3 Amgen Prostate Cancer Drugs Product Introduction
- 7.9.4 Amgen Response to COVID-19 and Related Developments
- 7.10 Bayer HealthCare
- 7.10.1 Bayer HealthCare Business Overview
- 7.10.2 Bayer HealthCare Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.10.3 Bayer HealthCare Prostate Cancer Drugs Product Introduction
- 7.10.4 Bayer HealthCare Response to COVID-19 and Related Developments
- 7.11 Ferring Pharmaceutical
- 7.11.1 Ferring Pharmaceutical Business Overview
- 7.11.2 Ferring Pharmaceutical Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.11.3 Ferring Pharmaceutical Prostate Cancer Drugs Product Introduction
- 7.11.4 Ferring Pharmaceutical Response to COVID-19 and Related Developments
- 7.12 Janssen Pharmaceuticals
- 7.12.1 Janssen Pharmaceuticals Business Overview
- 7.12.2 Janssen Pharmaceuticals Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.12.3 Janssen Pharmaceuticals Prostate Cancer Drugs Product Introduction
- 7.12.4 Janssen Pharmaceuticals Response to COVID-19 and Related Developments
- 7.13 Endo Pharmaceuticals
- 7.13.1 Endo Pharmaceuticals Business Overview
- 7.13.2 Endo Pharmaceuticals Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.13.3 Endo Pharmaceuticals Prostate Cancer Drugs Product Introduction
- 7.13.4 Endo Pharmaceuticals Response to COVID-19 and Related Developments
- 7.14 BMS
- 7.14.1 BMS Business Overview
- 7.14.2 BMS Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.14.3 BMS Prostate Cancer Drugs Product Introduction
- 7.14.4 BMS Response to COVID-19 and Related Developments
- 7.15 Takeda Pharmaceuticals
- 7.15.1 Takeda Pharmaceuticals Business Overview
- 7.15.2 Takeda Pharmaceuticals Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.15.3 Takeda Pharmaceuticals Prostate Cancer Drugs Product Introduction
- 7.15.4 Takeda Pharmaceuticals Response to COVID-19 and Related Developments
- 7.16 Northwest Biotherapeutics
- 7.16.1 Northwest Biotherapeutics Business Overview
- 7.16.2 Northwest Biotherapeutics Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.16.3 Northwest Biotherapeutics Prostate Cancer Drugs Product Introduction
- 7.16.4 Northwest Biotherapeutics Response to COVID-19 and Related Developments
- 7.17 Teva Pharmaceutical
- 7.17.1 Teva Pharmaceutical Business Overview
- 7.17.2 Teva Pharmaceutical Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.17.3 Teva Pharmaceutical Prostate Cancer Drugs Product Introduction
- 7.17.4 Teva Pharmaceutical Response to COVID-19 and Related Developments
- 7.18 Boehringer Ingelheim
- 7.18.1 Boehringer Ingelheim Business Overview
- 7.18.2 Boehringer Ingelheim Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.18.3 Boehringer Ingelheim Prostate Cancer Drugs Product Introduction
- 7.18.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
- 7.19 Foresee Pharmaceuticals
- 7.19.1 Foresee Pharmaceuticals Business Overview
- 7.19.2 Foresee Pharmaceuticals Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.19.3 Foresee Pharmaceuticals Prostate Cancer Drugs Product Introduction
- 7.19.4 Foresee Pharmaceuticals Response to COVID-19 and Related Developments
- 7.20 Tokai Pharmaceuticals
- 7.20.1 Tokai Pharmaceuticals Business Overview
- 7.20.2 Tokai Pharmaceuticals Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.20.3 Tokai Pharmaceuticals Prostate Cancer Drugs Product Introduction
- 7.20.4 Tokai Pharmaceuticals Response to COVID-19 and Related Developments
- 7.21 Spectrum Pharmaceuticals
- 7.21.1 Spectrum Pharmaceuticals Business Overview
- 7.21.2 Spectrum Pharmaceuticals Prostate Cancer Drugs Quarterly Production and Revenue, 2020
- 7.21.3 Spectrum Pharmaceuticals Prostate Cancer Drugs Product Introduction
- 7.21.4 Spectrum Pharmaceuticals Response to COVID-19 and Related Developments
8 Supply Chain and Sales Channels Analysis
- 8.1 Prostate Cancer Drugs Supply Chain Analysis
- 8.1.1 Prostate Cancer Drugs Supply Chain Analysis
- 8.1.2 Covid-19 Impact on Prostate Cancer Drugs Supply Chain
- 8.2 Distribution Channels Analysis
- 8.2.1 Prostate Cancer Drugs Distribution Channels
- 8.2.2 Covid-19 Impact on Prostate Cancer Drugs Distribution Channels
- 8.2.3 Prostate Cancer Drugs Distributors
- 8.3 Prostate Cancer Drugs Customers
9 Key Findings
10 Appendix
- 10.1 About Us
Summary:
Get latest Market Research Reports on Prostate Cancer Drugs . Industry analysis & Market Report on Prostate Cancer Drugs is a syndicated market report, published as Global (United States, European Union and China) Prostate Cancer Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Prostate Cancer Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
